Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Minocycline hydrochloride
Drug ID BADD_D01472
Description Minocycline was first described in the literacture in 1966.[A190681] It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria.[A190723] Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.[A190723] Minocycline was granted FDA approval on 30 June 1971.[L11695]
Indications and Usage Oral and topical minocycline are indicated to treat inflammatory lesions of acne vulgaris.[L11701,L11704,L11719] Subgingival microspheres are indicated as an adjunct treatment in the reduction of pocket depth in adults with periodontitis.[L11716] Oral and intravenous formulations are indicated to treat infections of susceptible microorganisms.[L11707,L11710,L11713] These include rickettsiae, _Mycoplasma pneumoniae_, _Chlamydia trachomatis_, _Chlamydophila psittaci_, _Chlamydia trachomatis_, _Ureaplasma urealyticum_, _Borrelia recurrentis_, _Haemophilus ducreyi_, _Yersinia pestis_, _Francisella tularensis_, _Vibrio cholerae_, _Campylobacter fetus_, _Brucella_ species, _Bartonella bacilliformis_, _Klebsiella granulomatis_, _Escherichia coli_, _Enterobacter aerogenes_, _Shigella_ species, _Acinetobacter_ species, _Haemophilus influenzae_, and _Kelbsiella_ species.[L11710]
Marketing Status approved; investigational
ATC Code J01AA08; A01AB23; D10AF07
DrugBank ID DB01017
KEGG ID D00850
MeSH ID D008911
PubChem ID 54685925
TTD Drug ID D08LTU
NDC Product Code 50909-9201; 65862-554; 42546-771; 55111-639; 57664-852; 64380-156; 68071-2225; 68071-2866; 68180-381; 68382-531; 69489-122; 70934-802; 72143-223; 0781-5387; 99207-464; 99207-467; 44657-0081; 65862-557; 0115-9936; 42546-777; 55111-637; 57664-853; 61919-270; 63629-9214; 65862-884; 65976-100; 67877-436; 67877-576; 68071-2311; 68382-551; 68788-7052; 69489-121; 70934-886; 71335-0682; 0591-3153; 71335-1237; 0591-5695; 0781-5386; 80425-0314; 17158-0900; 44657-0051; 65862-211; 65862-555; 73309-310; 13668-483; 50090-2339; 51655-753; 55289-201; 55700-415; 63629-9215; 67877-437; 67877-577; 68180-380; 68382-533; 69489-123; 57664-854; 59651-339; 63629-9213; 65862-209; 65862-885; 70518-2943; 71205-272; 0781-5385; 59651-338; 13668-485; 42546-774; 47781-544; 55289-202; 61919-845; 63629-9210; 64380-155; 67296-1181; 71335-0046; 71335-1045; 71403-102; 58623-0133; 65862-558; 13668-487; 57664-856; 63187-036; 65862-210; 67877-643; 67877-644; 68382-318; 68382-552; 70771-1427; 70842-160; 70934-673; 71335-1123; 0591-5694; 72143-221; 99207-463; 99207-465; 58159-085; 68225-074; 73402-112; 13668-482; 13668-486; 53002-2880; 55111-638; 63187-450; 63187-850; 64380-154; 65862-556; 67877-438; 68180-379; 68382-316; 68382-317; 70771-1157; 71205-511; 71335-0570; 72143-222; 0115-9935; 43063-736; 43353-105; 43353-172; 65862-883; 68071-5262; 68180-460; 70771-1138; 70771-1155; 70771-1428; 71205-086; 71403-101; 72162-1840; 99207-466; 47781-546; 57664-851; 59651-337; 60687-336; 63629-9208; 63629-9211; 63629-9212; 67877-578; 68382-535; 70518-1336; 70771-1156; 50909-9101; 51927-2197; 50090-0632; 57664-855; 63629-9209; 68788-8265; 70771-1167; 70771-1426; 0904-6888; 13668-484; 47781-545; 53002-2210; 58118-0484
UNII 0020414E5U
Synonyms Minocycline | Minox 50 | Aknemin | Aknin-Mino | Aknin Mino | Aknosan | Mynocine | Apo-Minocycline | Apo Minocycline | Arestin | Blemix | Cyclomin | Cyclops | Dentomycin | Dynacin | Icht-Oral | Icht Oral | Klinomycin | Lederderm | Mestacine | Minakne | Mino-Wolff | Mino Wolff | Minocin | Minocin MR | Minoclir | Minocycline Hydrochloride | Hydrochloride, Minocycline | Minocycline Monohydrochloride | Monohydrochloride, Minocycline | Minocycline, (4R-(4 alpha,4a beta,5a beta,12a beta))-Isomer | Minolis | Minomycin | Minoplus | Minotab | Akamin | Akne-Puren | Akne Puren
Chemical Information
Molecular Formula C23H28ClN3O7
CAS Registry Number 13614-98-7
SMILES CN(C)C1C2CC3CC4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Stevens-Johnson syndrome10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.005--
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.004--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thyroid function test normal13.10.06.005--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tooth discolouration07.09.02.001--
Urticaria23.04.02.001; 10.01.06.001--
Vertigo17.02.12.002; 04.04.01.003--
Hypoacusis04.02.01.006--
Lupus-like syndrome10.04.03.003; 23.03.02.004; 15.06.02.004--Not Available
Thyroid cancer16.24.03.001; 05.02.05.001--Not Available
Acute kidney injury20.01.03.016--
Drug reaction with eosinophilia and systemic symptoms12.03.01.064; 23.03.05.005; 10.01.01.021--Not Available
Fixed eruption08.01.06.025; 23.03.05.008; 10.01.01.037--Not Available
Idiopathic intracranial hypertension17.07.02.011--Not Available
The 2th Page    First    Pre   2    Total 2 Pages